UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Cancer treatment reviews, ISSN 0305-7372, 2014, Volume 40, Issue 7, pp. 862 - 871
Hematology, Oncology and Palliative Medicine | Estrogen receptor | Endocrine resistance | PI3K | Mammalian target of rapamycin | mTOR | Endocrine therapy | Luminal type | Breast cancer | AKT | Phosphatidylinositol 3-kinase | MTOR | Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Pharmacology. Drug treatments | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Receptors, Estrogen - metabolism | Signal Transduction - drug effects | TOR Serine-Threonine Kinases - metabolism | Humans | Female | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Proto-Oncogene Proteins c-akt - metabolism | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinase - metabolism | Breast Neoplasms - metabolism | Phenols | Development and progression | Chemotherapy | Estrogen | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 461 - 471
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Biomarkers, Tumor - metabolism | Breast Neoplasms - mortality | Female | Receptor, ErbB-2 - antagonists & inhibitors | Biomarkers, Tumor - antagonists & inhibitors | Molecular Targeted Therapy - methods | Trastuzumab | Patient outcomes | Analysis | Oncology, Experimental | Breast cancer | Metastasis | Research | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 20, pp. 1929 - 1940
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug therapy | Development and progression | Breast cancer | Cyclin-dependent kinases | Diarrhea | Endocrine therapy | Metastasis | Kinases | Patients | Cancer therapies | Survival | ErbB-2 protein | Fulvestrant | Hyperglycemia | Chemotherapy | Epidermal growth factor | Antitumor activity | Diabetes | Mutation | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 640 - 647
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Follow-Up Studies | Inflammatory Breast Neoplasms - pathology | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Antineoplastic Agents - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Genes, erbB-2 | Inflammatory Breast Neoplasms - drug therapy | Adult | Breast Neoplasms - mortality | Female | Neoadjuvant Therapy | Aged | Chemotherapy, Adjuvant | Trastuzumab | Inflammatory Breast Neoplasms - mortality | Antimitotic agents | Care and treatment | Breast cancer | Antineoplastic agents | Analysis | Chemotherapy | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 8, pp. 724 - 734
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Survival Analysis | Adult | Breast Neoplasms - mortality | Female | Aged | Receptor, ErbB-2 | Infusions, Intravenous | Trastuzumab | Care and treatment | Pertuzumab | Docetaxel | Breast cancer | Dosage and administration | Diagnosis | Research | Chemotherapy | Epidermal growth factor | Sensitivity analysis | Survival | ErbB-2 protein | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 377 - 384
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Antibodies, Monoclonal, Humanized | Fluorouracil - administration & dosage | Time Factors | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Receptor, ErbB-2 - drug effects | Doxorubicin - administration & dosage | Proportional Hazards Models | Combined Modality Therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 - genetics | Methotrexate - administration & dosage | Infusions, Intravenous | Trastuzumab | Chemotherapy | Breast cancer | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1269 - 1278
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Bevacizumab | Patient Selection | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Neoplasm Invasiveness - pathology | Adult | Remission Induction - methods | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Retreatment | Maximum Tolerated Dose | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Genes, erbB-2 - genetics | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Medical colleges | Care and treatment | Relapse | Chemotherapy | Breast cancer | Metastasis | Angiogenesis inhibitors | Diseases | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogens | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article